A Phase 4 interventional study of infliximab therapeutic drug monitoring in Crohn Disease and Ulcerative Colitis, sponsored by Imelda GI Clinical Research Center. Completed at 2 sites in Belgium. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by Imelda GI Clinical Research Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.
Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 94th largest by enrollment of the 175 interventional ones that give a count, is one of 15 that started in 2018, is one of 9 in phase 4, and was the 135th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Janssen Research & Development, LLC · Sites in Belgium, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 94 · Phase 4 9
First in 2001; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 211 across the 175 interventional studies, 257 across the 19 observational. Of the 135 that completed or were terminated, 83 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 194 have an industry lead sponsor. The 10 most frequent:
Imelda GI Clinical Research Center is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Imelda GI Clinical Research Center has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in Belgium that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 194 studies in Crohn Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a comparative pragmatic trial in patients with UC and CD on maintenance treatment with IFX. All IBD patients from cohort A with maintenance IFX treatment at a referral IBD clinic are prospectively included between June and August 2018. An ultra-proactive IFX TDM algorithm is applied as follows. All patients have an ELISA TL measurement at baseline, of which the result determined the follow-up pathway: (A) TL between 3-7μg/mL: continuation at same dose and interval; (B) TL >7μg/mL: interval prolongation allowed; (C) TL \<3μg/mL: interval shortening with minimum 2 weeks, with the next IFX TL measured using a POCT. (i) If the POCT showed an IFX TL \<3μg/mL, dose was optimized ad hoc using a linear dosing formula (Dosen = (TL target * Dose n-1) / TL measured), followed by a new POCT test at next visit with the same interval. (ii) If the POCT showed an IFX TL ≥3µg/mL, no additional dose was given and routine TL testing with ELISA was retaken at next visit. At every visit this algorithm was reapplied to all patients.
The patients from cohort A will be compared with the patients from cohort B. The patients in cohort B receive maintenance IFX treatment at a referral IBD clinic during the same period. Dose adjustment are done based on standard of care reactive TDM of IFX and clinical symptoms. Data will be collected retrospectively to avoid treatment optimization bias.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: infliximab therapeutic drug monitoring
Biological: infliximab therapeutic drug monitoring
dose optimization of infliximab based on a predefined dosing algorithm
number of patients with infliximab failure
number of patients with infliximab failure after one year (infliximab failure = infliximab discontinuation, IBD related surgery, IBD related hospitalization, add-on IBD treatment, and allergic reaction to infliximab)
Time frame: one year
number of TL measurements per patient per year
Time frame: one year
percentage of interval changes (shortening, prolongation, bidirectional)
Time frame: one year
number of patients with infliximab discontinuation
number of patients with discontinuation of infliximab
Time frame: one year
percentage of patients with sustained clinical remission
number of patients with physician global assessment \<1 and all visits
Time frame: one year
number of patients with mucosal remission
number of patients with mucosal remission after one year. (Mucosal remission = simple endoscopic score for CD \<3, Rutgeertscore \<i2 for, Mayo endoscopic subscore \<1 and faecal calprotectin \<250 µg/ml. Endoscopy and/or faecal calprotectin between 6 and 12 months after inclusion. If endoscopy and faecal calprotectin at the same moment, then endoscopy was dominant)
Time frame: one year
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2018 to primary completion in Aug 2019, 14 months.
Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's 14 months is below that.
Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imelda GI Clinical Research Center